FindTrial
Sign In

Management and improvement by ARB with Ca channel blocker in hypertensive patients with diabetes STUDY

Management and improvement by ARB with Ca channel blocker in hypertensive patients with diabetes STUDY - MINATO STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000003576
Enrollment
30
Registered
2010-05-10
Start date
2011-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive patients with diabetes

Interventions

At study entry, administrating ARB and Calcium channel blocker will be changed to Olmesartan (20 mg/day) and Azelnidipine (16 mg/day) and administered for 3 months. The drugs will be then switched to

Sponsors

The Jikei University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Hypertention patients with type 2 diabetes mellitus.

Exclusion criteria

Exclusion criteria: Contraindication of Olmesartan and Valsartan. Contraindication of Azelnidipin and Amlodipin

Design outcomes

Primary

MeasureTime frame
Blood pressure:Systolic Blood Pressure, Diastolic Blood Pressure.Home Blood Pressure(Conforming to JSH2009) Central Blood Pressure Heart rate Smoking History Augmentaion index (AIx) Cardio Ankle Vascular Index(CAVI) Salt excretion In Spot Urine Urinary albumin Urinary creatinine Urinary sodium Urinary Potassium Serum Creatinine Serum Sodium Serum Potassium Plasma Aldosterone Concentration PAI-1 Plasma Renin Activity—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026